Nektar Therapeutics (NKTR): NKTR-181 Advisory Committee Meeting
First and foremost, Nektar Therapeutics will be sitting in on an FDA Advisory Committee Meeting surrounding NKTR-181. The original PDUFA date for the drug was August 29, 2019. However, the FDA missed this date due to the Advisory Committee Meeting being postponed. A new meeting date has been set for January 14, 2020.
NKTR-181, also known as loxicodegol, is a novel mu-opioid agonist molecule. The drug has been designed to slow the rate of entry to the brain. As a result, the pain reliever should have a lower instance of abuse and related side effects.
The drug is on the table as a potential option for adult patients with low back pain that are beginning to be introduced to opioid medication.
Clinical studies surrounding NKTR-181 have shown some very positive results. In particular, not only has the treatment shown in clinical studies that it is effective in reducing pain, but it has also shown a reduced risk of abuse.
Considering the current opioid epidemic, and the positive data that has been released, there’s a good chance that the FDA’s Advisory Committee will vote for approval here.
Click below to continue reading.